Abstract
Treatment related fluctuation (TRF) poses a special challenge in the treatment of Guillain-Barre syndrome (GBS). Many cases of GBS following COVID-19 infection have been reported in literature till date, but treatment related fluctuation (TRF) in post COVID-19 GBS has not been reported till date. We report a 35-year-old male patient who developed GBS following COVID-19 infection and had TRF after intravenous immunoglobulin (IV-IG) therapy. He required ventilator support but repeat IV-IG therapy led to complete recovery. Significant proximal muscle involvement, cranial nerve palsy, no antecedent diarrhea and absence of anti-GM1 antibodies are important predictors of TRF in GBS and need to be recognized early in the course of this illness. Early recognition of TRF and differentiating it from other forms of immune mediated neuropathy such as acute onset chronic inflammatory demyelinating polyradiculoneuropathy (A-CIDP) are important for prognostication and management.
Keywords: Anti-GM1 antibodies; COVID-19; Guillain-Barre syndrome; Intravenous immunoglobulin; Treatment related fluctuation.
【저자키워드】 COVID-19, Intravenous immunoglobulin, Guillain-barrè syndrome, Anti-GM1 antibodies, Treatment related fluctuation., 【초록키워드】 Treatment, therapy, antibody, diarrhea, immune, COVID-19 infection, management, male, Patient, predictor, Inflammatory, complete recovery, Support, ventilator, TRF, fluctuation, Course, reported, required, form, absence, Significant, cranial, proximal muscle, 【제목키워드】 therapy, fluctuation,